ArticleThe Journal of innovations in cardiac rhythm management2026
Artificial Intelligence-guided Extra-pulmonary Vein Repeat Ablation with the Pentaspline Pulsed Field Ablation Catheter.
Article in The Journal of innovations in cardiac rhythm management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter from the Editor in Chief.The Journal of innovations in cardiac rhythm management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The safety and efficacy of pulsed field ablation (PFA) for cardiac ablation have been demonstrated in pulmonary vein (PV) isolation (PVI), but its relevance to target additional extra-PV substrate is still under investigation. We conducted a pilot, prospective, single-center, nonrandomized study in 25 patients with atrial fibrillation despite previous catheter ablation (52% men; 74 ± 9 years of age). Patients underwent catheter ablation using PFA with the goal of ablating artificial intelligence (AI)-guided spatiotemporal dispersion. Biatrial mapping of spatiotemporal dispersion was obtained using the Volta AF-Xplorer™ (Volta Medical, Providence, RI, USA). Re-conducting PVs and extra-PV regions of interest exhibiting dispersion were ablated using the Farawave™ catheter (Boston Scientific, Marlborough, MA, USA). This catheter was used either in the basket or flower configuration sequentially centered at an estimated geometric center of AI-detected dispersion regions. The mean procedure and biatrial mapping times were 75 ± 12 and 14 ± 7 min, respectively, and no fluoroscopy was used. No complications occurred, and sinus rhythm conversion by ablation was obtained in 23 patients (92%). The rate of freedom from any atrial arrhythmia at 6 months was 88%. In conclusion, we observed that PFA for personalized, AI-guided extra-PV dispersion repeat ablation appears safe and procedurally efficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.